Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation

Julius K Weng, Xiudong Lei, Pamela Schlembach, Elizabeth S Bloom, Simona F Shaitelman, Isidora Y Arzu, Gregory Chronowski, Tomas Dvorak, Emily Grade, Karen Hoffman, George Perkins, Valerie K Reed, Shalin J Shah, Michael C Stauder, Eric A Strom, Welela Tereffe, Wendy A Woodward, Gabriel N Hortobagyi, Kelly K Hunt, Thomas A Buchholz, Benjamin D Smith, Julius K Weng, Xiudong Lei, Pamela Schlembach, Elizabeth S Bloom, Simona F Shaitelman, Isidora Y Arzu, Gregory Chronowski, Tomas Dvorak, Emily Grade, Karen Hoffman, George Perkins, Valerie K Reed, Shalin J Shah, Michael C Stauder, Eric A Strom, Welela Tereffe, Wendy A Woodward, Gabriel N Hortobagyi, Kelly K Hunt, Thomas A Buchholz, Benjamin D Smith

Abstract

Purpose: There are limited prospective data on predictors of patient-reported outcomes (PROs) after whole-breast irradiation (WBI) plus a boost. We sought to characterize longitudinal PROs and cosmesis in a randomized trial comparing conventionally fractionated (CF) versus hypofractionated (HF) WBI.

Methods and materials: From 2011 to 2014, women aged ≥40 years with Tis-T2 N0-N1a M0 breast cancer who underwent a lumpectomy with negative margins were randomized to CF-WBI (50 Gray [Gy]/25 fractions plus boost) versus HF-WBI (42.56 Gy/16 fractions plus boost). At baseline (pre-radiation), at 6 months, and yearly thereafter through 5 years, PROs included the Breast Cancer Treatment Outcome Scale (BCTOS), Functional Assessment of Cancer Therapy-Breast (FACT-B), and Body Image Scale; cosmesis was reported by the treating physician using Radiation Therapy Oncology Group cosmesis values. Multivariable mixed-effects growth curve models evaluated associations of the treatment arm and patient factors with outcomes and tested for relevant interactions with the treatment arm.

Results: A total of 287 patients were randomized, completing a total of 14,801 PRO assessments. The median age was 60 years, 37% of patients had a bra cup size ≥D, 44% were obese, and 30% received chemotherapy. Through 5 years, there were no significant differences in PROs or cosmesis by treatment arm. A bra cup size ≥D was associated with worse BCTOS cosmesis (P < .001), BCTOS pain (P = .001), FACT-B Trial Outcome Index (P = .03), FACT-B Emotional Well-being (P = .03), and Body Image Scale (P = .003) scores. Physician-rated cosmesis was worse in patients who were overweight (P = .02) or obese (P < .001). No patient subsets experienced better PROs or cosmesis with CF-WBI.

Conclusions: Both CF-WBI and HF-WBI confer similar longitudinal PROs and physician-rated cosmesis through 5 years of follow-up, with no relevant subsets that fared better with CF-WBI. This evidence supports broad adoption of hypofractionation with boost, including in patients receiving chemotherapy and in a population with a high prevalence of obesity. The associations of large breast size and obesity with adverse outcomes across multiple domains highlight the opportunity to engage at-risk patients in lifestyle intervention strategies, as well as to consider alternative radiation treatment regimens.

Trial registration: ClinicalTrials.gov NCT01266642.